Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03585725 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma
A Early Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT03585725 is a Early Phase 1 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 3 participants.
The verdict
NCT03585725, a Early Phase 1 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma
Interventions
- DRUG Ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-09-26 |
| Est. Completion | 2020-07-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03585725
The ClinicalTrials.gov registry entry for NCT03585725 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ribavirin is the first listed.
NCT03585725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03585725 about?
NCT03585725 is a clinical study titled "A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma". This is a A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma
What is the current status of trial NCT03585725?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2018-09-26. Estimated completion is 2020-07-22.
What interventions are being tested in trial NCT03585725?
The interventions under investigation include: Ribavirin (DRUG).
Who is sponsoring clinical trial NCT03585725?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.